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Standard treatment duration for drug-susceptible tuberculosis (TB) treatment is 6 months. 
Treatment duration is often extended – and for various different reasons. The aim of this 
study was to determine the prevalence and to assess risk factors associated with extended 
TB treatment.
Methods
A cross-sectional study was conducted. Data including demographic, clinical, radiological 
and microbiological information from the Netherlands TB Register (NTR) of 90 patients with 
smear and culture positive pulmonary TB of the region Haaglanden, The Netherlands, was 
eligible for analysis.
Results
Treatment was extended to ≥ 200 days by 46 (51%) patients. Extended TB treatment was 
associated with a higher frequency of symptoms, presumed to be due to adverse drug 
reactions (ADR; OR 2.39 95% CI: 1.01-5.69), drug-induced liver injury (DILI) (OR: 13.51; 95% 
CI: 1.66-109.82) and longer than 2 month smear and culture conversion rate (OR: 11.00; 
95% CI: 1.24-97.96 and OR: 8.56; 95% CI: 1.53-47.96). In the multivariable logistic analysis, 
development of DILI emerged as the single statistically strong risk factor necessitating 
extension of TB treatment.
Conclusion
This finding will need further confirmation in a prospective study, exploring the possible 
mutual role of pharmacokinetic and pharmacogenetic determinants of DILI among TB 
patients.




According the World Health Organization (WHO) guidelines the aims of tuberculosis (TB) 
treatment are to cure the patient, to prevent death from active TB; to prevent relapse of 
TB; to reduce transmission of TB and to prevent the development and transmission of drug 
resistance TB strains 1. In general, TB treatment outcome is usually successful2,3, but some 
factors may have a negative impact on the course of the TB treatment: extent of disease, 
the drug of Mycobacterium tuberculosis (Mtb), previous TB treatment, comorbidity, use of 
more than six co-prescribed drugs and adverse drug reactions4-6. The application of Directly 
Observed Treatment (DOT) and improvement of TB treatment outcomes is still discussed 
as results differ among studies7-9. Several studies showed that suboptimal treatment 
resulted in a prolonged time to culture conversion and therefore increased duration of 
treatment10-12. The underlying problems may be the inter- and intra-individual variation in 
drug concentration; and the occurrence of adverse drug reactions (ADR)13,14. Early detection 
of risk factors predisposing for lack of treatment response or ADR is therefore priority during 
TB treatment.
Based on WHO and national Dutch guidelines, drug-susceptible TB should be treated for 6 
months: first a 2-month intensive phase with four drugs and then a 4-month continuation 
phase with two drugs1,15,16. However, in some situations this period should be extended. 
Prolonged treatment is indicated, for example, for patients with drug-susceptible 
pulmonary TB who have cavitation on the initial chest X-ray and still have positive sputum 
culture results at the end of the intensive phase17. Extension of TB treatment may improve 
treatment outcomes but it is presently unclear why these delayed therapeutic responses 
occur. If delayed response to treatment, or the occurrence of ADR, is driven by anti TB 
drug exposure, therapeutic drug monitoring (TDM) could help to detect such under- or 
overexposure18. TDM is not mentioned in WHO treatment guidelines and therefore not 
part of standard treatment. TDM has been used in in selected cases mainly in TB referral 
Centers19. TDM might impact on duration of therapy, assuming that identification of 
dose-related overexposure resulting in ADR requiring interruption of therapy, as well as 
underexposure resulting in delayed sputum culture conversion result in extended treatment 
duration. Before TDM is introduced in routine care it would help to identify the prevalence 
of extended treatment and risk factors associated with it.
The objective of this cross-sectional study was therefore to identify the prevalence and risk 






All patients from the region Haaglanden, The Netherlands, diagnosed with smear and culture 
positive pulmonary drug-sensitive TB in 2010-2013 and registered as having completed TB 
treatment, were eligible for inclusion in this study. Patients were treated by specialists of 
general hospital in our region or by specialist from TB department of the GGD (Municipal 
Public Health Service). Patients were excluded from the study, if (a) the surveillance data 
from the national tuberculosis registry could not be completed by in-patient medical 
records; (b) patient died during the treatment, or (c) were lost to follow-up.
Study design and methods
Anonymized surveillance data of all notified culture positive TB cases registered in region 
Haaglanden, between January 2010 and December 2013, were received from the NTR and 
supplemented with data obtained from patient’s medical records by the first author (NB). 
NB was attending physician at GGD Haaglanden and performed the combination of the 
data. Subsequently, identifiers were removed and the database was locked. Analyses were 
performed with anonymized data. Co-authors had only access to anonymized data.
Patients were divided into two groups based on duration of treatment. A ‘TB patient with 
prolonged treatment’ was defined as patient with smear- and culture- positive pulmonary 
drug-sensitive TB, treated ≥ 200 days. ‘Patients with standard TB treatment duration’ were 
defined as patients with smear- and culture positive pulmonary TB, treated ≤ 199 days. The 
cut-off of 200 days was chosen based on summation of 6 months of standard TB treatment 
plus 2 weeks. The addition of 2 weeks was chosen, because at least 2 weeks interruption 
of TB treatment in the intensive phase for any reason leads to reintroduction of intensive 
phase treatment and thereby to extension of total TB treatment duration.
We conducted a cross-sectional study with demographic, TB diagnosis and TB treatment 
patient characteristics. The following individual-level variables were studied: age, sex, 
weight, race, alcohol and drug addiction, disease site, presence of cavitary TB, history of TB 
treatment, time to sputum smear and culture conversion, creatinine level, implementation 
of DOT, suspicion of ADR based on symptoms, co-morbidity, DILI, hospitalization in TB 
referral center and TB treatment by TB Municipal Public Health Service or specialist from 
hospital.
Suspected ADR and DILI were defined by the treating physician and registered in patient’s 
medical records. The most common symptoms associated with suspected ADR reported 
were: pain in the upper abdomen or stomach, unusual tiredness or weakness, diarrhea, 
dizziness, nausea and vomiting, skin itching or rash, fever, arthralgia, numbness or tingling 
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in the hands or feet, blurred vision. The clinical presentation of DILI predominantly is acute 
hepatitis and/or cholestasis marked by increased values of alkaline phosphatase and/
or alanine aminotransferase and international normalized ratio. We composed one co-
morbidity group including patients with Diabetes Mellitus (DM), human immunodeficiency 
virus (HIV) and malignancy. Age was divided into two groups (≤34 and ≥ 35 years old) 
and weight into three groups (<50kg, 50-75 kg and >75kg) as defined in the national 
tuberculosis registry. Race was classified according to geographical affiliation: European / 
Caucasian background referred to patients who originated from countries above the line of 
sub-Saharan Africa, African referred to patients originating from countries in sub-Saharan 
Africa, Asian referred to origin from one of Asian countries.
As this was a retrospective study using routinely collected data, ethical clearance was not 
required under Dutch Law.
Analysis
Demographic characteristics of the two patients groups were described and tested for 
possible differences. Univariate logistic regression was performed for each individual 
variable of interest. We conducted logistic regression analysis to identify the frequency of 
each of the measured patient characteristics in each of the two groups, and to identify those 
associated with extended TB treatment. Variables that showed a significant association 
(P<0.05) in the univariate analysis and those that a priori were considered to be potential 
confounders as like suspicious symptoms for ADR and comorbidity were introduced in the 





Out of the 285 culture positive TB patients reported between January 2010 and December 
2013 in region Haaglanden, 102 (36%) patients had smear- and culture- positive pulmonary 
TB. In total follow-up data of 8 patients were not available, 2 patients had a final diagnosis 
of Nontuberculous Mycobacterial Disease and 2 died during the intensive phase of TB 
treatment. The cause of death of both patients was a combination of old age, underlying 
comorbidities and fulminant miliary TB. Thus 90 patients out of 102 were eligible for 
analysis: 46 patients were treated ≥ 200 days and 44 patients were treated ≤ 199 days 
(Fig.1). In 13 of 46 cases (28%) the extension of treatment occurred in the intensive phase. 
The distribution of demographics, TB diagnosis and patient characteristics between the 
two groups and crude ORs assessed for their association with extension of treatment are 
demonstrated in table 1.
 
Figure 1. Flow chart showing the participants included in the analysis.
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OR, odds ratio; CI, confidence interval; PTB, Pulmonary tuberculosis; EPTB, Extrapulmonary




The study groups did not differ in terms of ethnicity, gender and age. The median age of 
patients in both groups was similar, 32 versus 34 years. Caucasians prevailed in both groups. 
None of the demographic characteristics of patient groups were statistically significantly 
associated with extended treatment duration. Despite the high proportion of patients with 
DM treated ≥ 200 days, 8 versus 4 patients, co-morbidity also was not significantly associated 
with extension of treatment (OR=1,8; 95% CI 0.58-5.3). Besides, the group of patients 
treated ≥ 200 days included a higher proportion of patients with a combination of extra-
pulmonary and pulmonary TB; with cavitary lesions; and a history of previous TB treatment. 
These factors were not significantly associated either, although they demonstrated 
moderate positive association. Out of the 10 patients reported with EPTB 7 were from 
group of prolonged treatment: 2 with intrathoracic lymph node TB, 1 with laryngitis, 2 
with peripheral lymph node TB and 2 patients had a TB meningitis. Three patients from 
standard group had intrathoracic lymph node TB, pleural and cervical spinal TB respectively. 
The optimal duration of treatment of TB meningitis caused by susceptible strains is not 
defined. There are no clinical trials comparing a six-month to a longer treatment regimen 
for TB meningitis. Six- to nine-month regimes containing R for treatment of osteoarticular 
TB are at least as effective as 18-month regimens without R1. Both included patients with TB 
meningitis had complex interrelations between TB and comorbidity caused the extension 
of their treatment.
Typical finding in our study was the lack of microbiological tests. This can be explained by the 
absence of sputum production and the reluctance of clinicians to repeat bronchoalveolar 
lavage. In total 36 (40%) patients, 21 with extended treatment and 15 with standard 
treatment had a cavitation on the initial chest X-ray and just 6 (17%) of them, 5 from the 
group of extended treatment duration, and 1 from standard treatment duration, were still 
sputum smear positive at the end of the intensive phase. Presumed ADR was associated 
with extended treatment (OR 2.39, 95% CI: 1.01-5.7). The development of DILI was strongly 
associated with extended treatment duration (OR: 13.5; 95% CI: 1.7-109.8). Results of time 
of smear and culture conversion were available for 31 % and 39% of patients respectively. For 
those with results available, univariate regression analyses showed a significant association 
between longer than 2 month positive smear (OR: 11.00; 95% CI: 1.24-98) and culture 
conversion rate (OR: 8.56; 95% CI: 1.53-48) with extension of the total TB treatment duration. 
The results of the multivariable logistic regression analysis are presented in Table 2.
If we adjusted for the potential confounders time to culture conversion and co-morbidity, 
DILI remained associated with extension of treatment duration (OR=13.62, 95% CI 1.47-
126.6), but this association with symptoms indicative for ADR disappeared (OR=1.72, 95% 
CI 0.59-5).
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Table 2. Multivariable analysis: conditional logistic regression model for predictors of prolonged TB treatment. 
Unadjusted OR Adjusted OR 
Variable and category OR (0.95%CI) P- value OR (0.95%CI) P- value

















































To the best of our knowledge this is the first study to analyse predictors for prolonged TB 
treatment in a Dutch outpatient setting. Univariate analysis showed a statistically significant 
association between ‘symptoms’, DILI and smear and culture conversion more than two 
months after start of treatment with extended TB treatment duration. In multivariable 
analysis just one single factor- the development of DILI during the TB treatment - contributed 
significantly to the extension of TB treatment. It needs to be mentioned that we could only 
identify 11 patients with DILI and extended treatment that could be compared with 1 DILI 
patient without extended treatment time. This resulted in wide confidence intervals in 
logistic regression analysis. A larger study could be helpful to confirm this finding.
Nearly one in four patients (23%) from the group of patients treated ≥ 200 days in our study 
was registered with DILI during TB treatment, compared to 2% in the standard treatment 
group. This is in line with earlier publications that showed the risk of DILI in diverse studies 
to range from 5 to 33%20-22. The pathogenesis and types of DILI vary from hepatic adaptation 
to hepatocellular injury. Knowledge of the mechanism of TB DILI is still incomplete. The 
number of different studies on factors contributing to development of hepatotoxicity during 
the TB treatment indicated age, ethnicity, pregnancy, malnutrition, alcohol consumption, 
HIV and viral hepatitis as predictors of TB DILI18,23,24. 
In case of elevation of liver enzymes during the TB treatment, a serum level more than 
three times the upper limit of normal in the presence of symptoms, or more than five 
times the upper limit of normal in the absence of symptoms, an interruption of treatment 
CHAPTER 3
56
is recommended by different guidelines1,17. The variation of outcomes of DILI, ranging from 
spontaneous resolution to liver failure and death, can sometimes lead to extreme caution 
resulting in early interruption of treatment by clinicians. Reintroduction of treatment is 
possible if the level of liver enzymes has decreased to less than two times the upper limit of 
normal and symptoms have significantly improved. 
Multifaceted social issues are reported associated with adherence to TB treatment and 
treatment duration. Most of these social-related factors are country-specific. Therefore TB 
is known as the barometer of social welfare. Homeless, financial insecurity, lack of effective 
social support, criminality, and addiction problems make these patients more vulnerable 
and the treatment of TB more complicated25-27. The Netherlands as like most low-incidence 
countries has a relatively well-financed health system with favourable conditions for 
treatment of TB28. In the Netherlands all TB patients are supervised and supported during 
treatment by the public health nurse of the MPHS, using diverse case management 
interventions. Since 2007 the DOT coverage has reached nearly 80 % among unemployed 
patients and substance abusers, and 90% among the prison population. During the study 
period 2012-2013 the percentage of TB-patients in risk groups decreased further resulting 
in a stop of the periodic screening of drug addicts and homeless in Haaglanden region due 
to the low yield and therefore less effect of the screening29.
The WHO guideline does not suggest measurement of drug concentration in selected 
clinical cases like these and reintroduction schedules do not consider drug concentration 
measurements. It seems reasonable to measure the blood concentration of anti TB drugs 
in patients diagnosed with hepatic dysfunction, to be able to adapt the dose tailored to the 
individual patient. In this perspective the results of a recently published study from India 
are very remarkable. Satyaraddi et al. reported higher plasma level of Rifampicin (R) in 15 
TB patients who developed DILI in comparing with 95 patients who did not30. The maximum 
concentration of R with cut-off 12.50 mg/L predicted subsequent development of DILI in 
93.3% of the patient, which may prevent the occurrence of DILI. 
There are a number of on-going efforts in different fields of pathophysiology of this 
clinical complication. Studying the effect of genetic variation is one of them. Results 
of prospective randomized controlled study of Azuma and colleagues showed a great 
potential of the genotype-guided dosing stratification of Isoniazid (INH) in chemotherapy 
of TB and development of liver injury31. These conclusions are concordant with results of 
studies conducted by Sotsuka et al. and Wang et al. reporting drug-metabolizing enzyme 
polymorphisms and predisposition to DILI32,33. Moreover, several studies evaluated the 
relation between drug concentrations, drug metabolizing enzymes and toxicity. Although 
findings were consistent, showing toxicity at higher concentrations, a randomized controlled 
trial showing that TDM reduces DILI has not been performed34-36.
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In our study we have studied culture conversion rates as potential indicator of extended 
TB treatment, related to insufficient drug exposure. According to the WHO the extension 
of the TB therapy is recommended if sputum-culture examination at the end of the 
second month of treatment is still positive for patients who have cavitation on the initial 
chest radiograph. The presence of cavitary disease in our study did not have a significant 
association with extended treatment but this could have been caused by the small sample 
size. Twenty-four percent of the patients who received extended treatment had delay of 
sputum smear and culture conversion longer than 2 months. This outcome corresponded 
well with results of several epidemiological studies indicating that the proportion of TB 
patients who remain smear-positive after 2 months of treatment can be greater than 20% 
(3.3–25.3%)6,37-43. However, our multivariable regression analysis did not confirm significant 
differences in delay of culture conversion between our two groups. Data linking insufficient 
drug levels to delay of culture conversion is scarce. A retrospective cohort study of Heysell 
et al. conducted in Virginia, identified lower than expected levels of INH, R and Ethambutol 
(E) among patients with delayed treatment response44. Results of a prospective study of 
Pasipanodya et al. conducted in Western Cape, South Africa confirmed also the predictive 
role of low drug exposure in poor long-term clinical outcomes in 25% of TB patients45. As 
our study shows no difference in culture conversion rate it is unlikely that low drug exposure 
could have been the underlying cause of prolonged treatment. At this moment there is a 
growing understanding of the link between the plasma concentration of anti TB drugs and 
efficacy and adverse events and its potential role in the management of TB treatment46,47. 
As a result, in 2014, TBNET published a consensus statement of management of drug-
resistant TB in Europe, advising TDM with drug dose adjustment10. The Recently published 
clinical practice Guideline of ATS/CDC/IDSA for treatment of drug-susceptible TB, endorsed 
by European Respiratory Society, for the first time provides recommendations in which 
conditions or situations TDM might be helpful. Patients with a medical conditions suspected 
of leading to subtherapeutic or toxic drug concentrations is one of the examples48. 
The present study has several limitations that should be mentioned. An important limitation 
was the relatively small cohort study. The Netherlands is a low-burden TB country with 
incidence of tuberculosis 6,5 in 2010 decreased till 5,1 in 2013 with just around 20-23% 
patients with smear and culture positive pulmonary drug-sensitive TB. Moreover, TB in 
western European is concentrated in urban areas, specifically in the Netherlands in 4 big 
cities: The Hague, Rotterdam, Amsterdam and Utrecht, without significant difference in 
patient’s population49. Our findings based on data of TB patients from region Haaglanden 
would be not essentially different between the regions and therefore reflect the situation 
in the Netherlands, at least in period between 2010-2013. Due to the retrospective nature 
of the study patients ‘records were partly incomplete. The main reason was that part of 
the treatment was performed in a hospital or other public health region. Final results of 
these cases were reported in the NTR. Due to incomplete data we excluded these cases. 
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Although already known before start of the study, actual drug concentrations and values 
of minimal inhibitory concentrations were not available as these were not part of standard 
treatment. Lack of both microbiological tests can be partly explained, on the one hand, by 
the absence of sputum production, and on the other hand by the reluctance of clinicians to 
repeat bronchoscopic bronchoalveolar lavage, an invasive and patient unfriendly procedure. 
Despite these limitations the results of this study showing DILI as an independent risk factor 
for extended treatment justify a prospective study to detect whether pharmacokinetics and 
pharmacogenetics are associated with DILI. A better understanding of factors associated 
with delayed treatment response and ADR, may help to improve management of patients 
receiving TB treatment.
Conclusion
DILI was identified as a significant independent predictor of extended TB treatment. 
This study justifies a prospective investigation evaluating whether potential factors like 
pharmacokinetics and pharmacogenetics are associated with DILI. A better understanding 
of factors associated with DILI and delayed treatment response, may help to improve 
management of patients receiving TB treatment.
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